Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 15, 2022 07:50 ET | Source: Aerovate Therapeutics, Inc.

Aerovate Therapeutics Announces Second Quarter 2022 Financial Results

WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
June 02, 2022 08:00 ET | Source: Aerovate Therapeutics, Inc.

Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference

WALTHAM, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
May 16, 2022 17:15 ET | Source: Aerovate Therapeutics, Inc.

Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

AV-101 is being developed to address cellular hyperproliferation and resistance to apoptosis in the pulmonary vasculature, which are key features of the pathophysiology of PAH PAH is an area of high...
May 16, 2022 08:00 ET | Source: Aerovate Therapeutics, Inc.

Aerovate Therapeutics Announces First Quarter 2022 Financial Results

WALTHAM, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
March 30, 2022 16:45 ET | Source: Aerovate Therapeutics, Inc.

Aerovate Therapeutics Announces Full-Year 2021 Financial Results

Initiated IMPAHCT, a global Phase 2b/Phase 3 trial of AV-101 for pulmonary arterial hypertension (PAH) in December 2021Received FDA guidance in April 2021 that our Phase 2b/Phase 3 trial could support...
March 02, 2022 08:00 ET | Source: Aerovate Therapeutics, Inc.

Aerovate Therapeutics to Present at Cowen 42nd Annual Health Care Conference

WALTHAM, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
December 15, 2021 08:00 ET | Source: Aerovate Therapeutics, Inc.

Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension

WALTHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
November 15, 2021 08:00 ET | Source: Aerovate Therapeutics, Inc.

Aerovate Therapeutics Announces Third Quarter 2021 Financial Results

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
September 17, 2021 08:00 ET | Source: Aerovate Therapeutics, Inc.

Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index

WALTHAM, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...
August 16, 2021 08:00 ET | Source: Aerovate Therapeutics, Inc.

Aerovate Therapeutics Announces Second Quarter 2021 Financial Results

WALTHAM, Mass. , Aug. 16, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...